This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient—an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.
Get full access to this article
View all access options for this article.
References
1.
WeilH.M.Pharmacologic management of arrhythmias in critical care medicine: Interpreting the new ACLS guidelines. 30th International Scientific Symposium, Society of Critical Care Medicine. San Francisco, CA; February 11, 2001.
2.
Anonymous.Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: An international consensus on science.Circulation.2000; 102(suppl I): I-1–378.
3.
Anonymous.Answers and insights about application of guidelines 2000 for CPR and ECC.Currents.2001;12: 9–10.
4.
CumminsR.O., HazinskiM.F.The next chapter in the high-dose epinephrine story: Unfavorable neurologic outcomes?Ann Intern Med.1998; 129: 501–2.
5.
GueugniaudP.Y., MolsP., GoldsteinP.A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital.N Engl J Med.1998; 339: 1595–1601.
6.
BehringerW., KittlerH., SterzF.Cumulative epinephrine dose during cardiopulmonary resuscitation and neurologic outcome.Ann Intern Med.1998; 129: 450–6.
7.
TangW.Use of epinephrine as vasopressor agent during cardiopulmonary resuscitation: Another example of a double-edged sword.Crit Care Med.2000; 28: 1671–2.
8.
BabbsC.F., BergR.A., KetteF.Use of pressors in the treatment of cardiac arrest.Ann Emerg Med.2001; 37: S152–62.
9.
Anonymous.Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care.Currents.2000; 11: 3–27.
10.
LindnerK.H., DirksB., SrohmengerH.U.Randomized comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation.Lancet.1997; 349: 535–7.
11.
StiellI.G., HebertP.C., WellsG.A.Vasopressin versus epinephrine for inhospital cardiac arrest: A randomized controlled trial.Lancet.2001; 358: 105–9.
12.
MorleyP.Vasopressin or epinephrine: Which initial vasopressor for cardiac arrests?Lancet.2001; 358: 85–6.
13.
HerlitzJ., EkstromL.WennerblomB, Lidocaine in out-of-hospital fibrillations: Does it improve survival?Resuscitation.1997; 33: 199–205.
14.
WeaverW.D., FahrenbruchC.E., JohnsonD.D.Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation.Circulation.1990; 82: 2027–34.
15.
ZeislerJ., CampJ., GaarderT.Reconsideration of the routine and preferential use of lidocaine in the emergent treatment of ventricular arrhythmias. [letter].Crit Care Med.1993; 21: 305.
16.
DorianP., CassD., SchwartzB.Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation.N Engl J Med.2002; 346: 884–90.
17.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction.Lancet.1995; 345: 669–85.
18.
TeoK.K., YusufS., CollinsR.Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomized trials.BMJ.1991; 3030: 1499–503.
19.
WoodsK.L., FletcherS., RoffeC.Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2).Lancet.1992; 339: 1553–8.
20.
ThelM.C., ArmstrongA.L., McNultyS.E.Randomised trial of magnesium in in-hospital cardiac arrest.Lancet.1997; 350: 1272–6.
21.
FatovichD.M., PrenticeD.A., DobbG.J.Magnesium in cardiac arrest (the magic trial).Resuscitation.1997; 35: 237–41.
22.
KudenchukP.J., CobbL.A., CopassM.K.Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation.N Engl J Med.1999; 341: 871–8.
